



POWERING THE IMMUNE SYSTEM  
TO TRANSFORM LIVES

NEWS RELEASE

# Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

2024-10-17

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2024, on October 31, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on October 31, 2024.

The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at [www.vir.bio](http://www.vir.bio). Participants may access the conference call via webcast on the Events & Presentations page of Vir's website at <https://investors.vir.bio/events-presentations> or listen in by dialing the U.S. toll free number (888) 800-8770 or international +1 (646) 307-1953. Conference ID: 7568777. A recorded version of the call will be available on the website approximately two hours after the completion of the event and will be archived there for 30 days.

## About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir's clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections, in addition to multiple oncology programs. Vir also has a preclinical portfolio of programs across a range of other infectious diseases and oncologic malignancies. Vir routinely posts information that may be important to investors

on its website.

## Media

Arran Attridge

Senior Vice President, Corporate Communications

**aattridge@vir.bio**

## Investors

Richard Lepke

Senior Director, Investor Relations

**rlepke@vir.bio**

Source: Vir Biotechnology, Inc.